Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 80

Similar articles for PubMed (Select 16870043)

1.

K-ras mutations in non-small-cell lung carcinoma: a review.

Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao MS.

Clin Lung Cancer. 2006 Jul;8(1):30-8. Review.

PMID:
16870043
2.
3.

K-ras genotypes and prognosis in non-small-cell lung cancer.

Rosell R, Monzo M, Molina F, Martinez E, Pifarre A, Moreno I, Mate JL, de Anta JM, Sanchez M, Font A.

Ann Oncol. 1995;6 Suppl 3:S15-20.

PMID:
8616107
4.

Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.

Schiller JH, Adak S, Feins RH, Keller SM, Fry WA, Livingston RB, Hammond ME, Wolf B, Sabatini L, Jett J, Kohman L, Johnson DH.

J Clin Oncol. 2001 Jan 15;19(2):448-57.

PMID:
11208838
5.

A universal method for the mutational analysis of K-ras and p53 gene in non-small-cell lung cancer using formalin-fixed paraffin-embedded tissue.

Sarkar FH, Valdivieso M, Borders J, Yao KL, Raval MM, Madan SK, Sreepathi P, Shimoyama R, Steiger Z, Visscher DW, et al.

Diagn Mol Pathol. 1995 Dec;4(4):266-73.

PMID:
8634783
6.

Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapy.

Broermann P, Junker K, Brandt BH, Heinecke A, Freitag L, Klinke F, Berdel WE, Thomas M.

Cancer. 2002 Apr 1;94(7):2055-62.

7.

Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.

Rodenhuis S, Boerrigter L, Top B, Slebos RJ, Mooi WJ, van't Veer L, van Zandwijk N.

J Clin Oncol. 1997 Jan;15(1):285-91.

PMID:
8996154
8.

Implications and prognostic value of K-ras mutation for early-stage lung cancer in women.

Nelson HH, Christiani DC, Mark EJ, Wiencke JK, Wain JC, Kelsey KT.

J Natl Cancer Inst. 1999 Dec 1;91(23):2032-8.

9.

A fast and convenient new technique to detect the therapeutic target, K-ras mutant, from peripheral blood in non-small cell lung cancer patients.

Tsao DA, Yang MJ, Chang HJ, Yen LC, Chiu HH, Hsueh EJ, Chen YF, Lin SR.

Lung Cancer. 2010 Apr;68(1):51-7. doi: 10.1016/j.lungcan.2009.05.023. Epub 2009 Jul 8.

PMID:
19589613
10.

[K-RAS gene mutations in patients with non-small cell lung cancer].

Zhang Y, Pan Z, Zhang X, Xu F, Zhang L.

Zhongguo Fei Ai Za Zhi. 2010 Jun;13(6):602-6. doi: 10.3779/j.issn.1009-3419.2010.06.007. Chinese.

11.

Low frequency of p53 and k-ras codon 12 mutations in non-small cell lung carcinoma (NSCLC) tumors and surgical margins.

Vatan O, Bilaloglu R, Tunca B, Cecener G, Gebitekin C, Egeli U, Yakut T, Urer N.

Tumori. 2007 Sep-Oct;93(5):473-7.

12.

[Impact of KRAS in standard treatment of non-small cell lung cancer (NSCLC) patients in 2009: prognostic and predictive value].

Planchard D, Loriot Y, Besse B.

Bull Cancer. 2009 Dec;96 Suppl:S57-68. doi: 10.1684/bdc.2009.0997. French.

PMID:
20034871
13.

Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma.

Cho JY, Kim JH, Lee YH, Chung KY, Kim SK, Gong SJ, You NC, Chung HC, Roh JK, Kim BS.

Cancer. 1997 Feb 1;79(3):462-7.

PMID:
9028355
14.

Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.

Huang CL, Taki T, Adachi M, Konishi T, Higashiyama M, Kinoshita M, Hadama T, Miyake M.

Int J Oncol. 1998 Mar;12(3):553-63.

PMID:
9472092
15.

Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer.

Graziano SL, Gamble GP, Newman NB, Abbott LZ, Rooney M, Mookherjee S, Lamb ML, Kohman LJ, Poiesz BJ.

J Clin Oncol. 1999 Feb;17(2):668-75.

PMID:
10080613
16.

The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers.

Konishi T, Huang CL, Adachi M, Taki T, Inufusa H, Kodama K, Kohno N, Miyake M.

Int J Oncol. 2000 Mar;16(3):501-11.

PMID:
10675482
17.

Molecular staging of non-small cell lung cancer according to K-ras genotypes.

Rosell R, Monzó M, Pifarré A, Ariza A, Sánchez JJ, Moreno I, Maurel J, López MP, Abad A, de Anta JM.

Clin Cancer Res. 1996 Jun;2(6):1083-6.

18.

K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer.

Fukuyama Y, Mitsudomi T, Sugio K, Ishida T, Akazawa K, Sugimachi K.

Br J Cancer. 1997;75(8):1125-30.

19.

A novel molecular staging protocol for non-small cell lung cancer.

Miyake M, Adachi M, Huang C, Higashiyama M, Kodama K, Taki T.

Oncogene. 1999 Apr 8;18(14):2397-404.

20.

[A simple look at the molecular biology of lung cancer: K-Ras].

Lena H, Corre R, Denis M.

Rev Mal Respir. 2010 Jun;27(6):639-43. doi: 10.1016/j.rmr.2010.05.003. Epub 2010 Jun 11. French.

PMID:
20610078
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk